Antitrust risk-shifting provisions in NeoGenomics, Inc./Clarient, Inc. purchase agreement | Practical Law

Antitrust risk-shifting provisions in NeoGenomics, Inc./Clarient, Inc. purchase agreement | Practical Law

Antitrust risk-shifting provisions in NeoGenomics, Inc./Clarient, Inc. purchase agreement

Antitrust risk-shifting provisions in NeoGenomics, Inc./Clarient, Inc. purchase agreement

October 20, 2015 • Antitrust Risk-shifting • $275.2 million (approximate deal value based on price of Buyer Guarantor common stock on signing date and press release; subject to purchase price adjustment).
End of Document

© 2024 Thomson Reuters. No claim to original U.S. Government Works.